



Docket No. T2315-907327US02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Laszlo Prokai

Serial No.: 10/801,695 : Art Unit:

Filed: March 17, 2004

For: Antagonists of RF-Amide Neuropeptides : Examiner:

### **INFORMATION DISCLOSURE STATEMENT**

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with Applicants duty of disclosure, the following information is submitted for consideration by the U.S. Patent and Trademark Office in connection with the above-identified application.

Since this statement is filed after three (3) months of the filing date of this application, but prior to the mailing of the first office action, no fee is believed to be required.

The application relies, under 35 USC §120, on the earlier filing date of prior U.S. Application Serial No. 10/109,000, filed March 29, 2002. The references identified on the attached Form PTO-1449 were submitted to and/or cited by the applicant or the Patent Office in the prior application and, therefore copies are not required to be provided. (see 37 CFR §1.98(d)).

It is respectfully requested that the Examiner fully consider each of the documents, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the document has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

MILES & STOCKBRIDGE

Dennis P. Clarke

Registration No. 22,549

Filed: June 18, 2004

Customer No. 000181

1751 Pinnacle Drive

Suite 500

McLean, Virginia 22102-3833

Telephone:

(703) 903-9000

Facsimile:

(703) 610-8686

Sheet 1 of 3

Sheet 1 of 3

ATTY. DOCKET NO. T2315-907327US02

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE GROUP ART UNIT 1624

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	4,988,701	1/29/1991	Olney	514	318	8/25/89
	5,011,853	4/30/1991	Olney	514	454	1/26/90
	6,323,239	11/27/2001	Dewey et al.	514	561	8/9/00
	6,541,520	4/1/2003	Dewey et al.	514	561	12/11/98
	6,562,364	5/13/2003	DiSanto et al.	424	434	3/13/01
	6,566,400	5/20/2003	Akunne et al.	514	561	8/29/00
	6,593,367	7/15/2003	Dewey et al.	514	561	7/28/99

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE
	2,002,006,274	1/2002	WO [by Sum, Fuk-Wah et al.]			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

· <del>-</del>	·	

EXAMINER	DATE CONSIDERED
· · · · · · · · · · · · · · · · · · ·	

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.

PTO-1449 (Modified)	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER 10/801, 695
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPLICANT	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Laszlo Prokai	
	FILING DATE March 17, 2004	GROUP ART UNIT

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Elshourbagy, et al., J. Biol. Chem. Chem. 2000, 275, 25965-25971
 Bonini, et al., J. Biol. Chem. 2000, 275, 39324-39331
Yang et al., Proc. Natl. Acad. Sci., 1985, 82, 7757-61
Yang et al., Prog. Clin. Biol. Res., 1985, 192, 313-22
 Panula et al., Med. Biology, 1987, 65, 127-35
Kivipelto et al., Journal of Comparative Neurology
 Ferrarese et al., Regulatory Peptides, 1986, 13, 245-52
 Tang et al., Proc. Natl. Acad. Sci., 1984, 81, 5002-5
Kavaliers et al., Peptides, 1989, 10, 741-5
Kavaliers et al., Peptides, 1991, 12, 235-239
Malin et al., Peptides, 1990, 11, 969-972
Malin et al., Peptides, 1990, 11, 277-280
Malin et al., Peptides, 1991, 12, 1011-4
 Malin et al., Drug Alcohol Depend. 1995, 40, 37-42
 Guzman et al., Neuropeptides 1989, 14, 253-261
Majane et al., Peptides, 1987, 8, 657-662
 Majane et al., Peptides, 1988, 9, 1137-1144
Majane et al., Peptides, 1990, 11, 969-972
Allard et al., Brain Res., 1989, 500, 169-176
Rothman, Synapse 1992, 12, 129-138
Lake et al., Neurosci. Lett. 1991, 132, 29-32
Payza, Peptides, 1987, 8, 1065-1074

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

# PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT Laszlo Prokai FILING DATE March 17, 2004 SERIAL NUMBER 10/801,695 SERIAL NUMBER 10/801,695 GROUP ART UNIT 1624

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Tan et al., Peptides 1999, 20, 1211-1217
	Gicquel et al., J. Med. Chem. 1994, 37, 3477-3481
	Weiner et al., Comput. Chem. 1986, 7, 230-252
	Stewart, J. Comput. Chem. 1989, 10, 209-220
	Houghten et al., J. Med. Chem. 1999, 42, 3743-3778
	Furka et al., J. Pept. Protein Res. 1991, 37, 487-493
	Lipinski et al., Adv. Drug. Deliv. Rev. 1997, 23, 3-25
	Ghose et al., J. Comput. Chem. 1988, 9, 80-90
	Pidgeon et al., J. Med. Chem. 1995, 38, 590-594
	Reichel et al., Pharm. Res. 1998, 15, 1270-1274
	Lingford et al., PubMed Abstract 12697627, also cited as Br. Med. Bull., 65,209-22(2003)
	Cador et al., PubMed 11958872, also cited as Neuroscience, 110/2,309-18(2002)
	Malin et al., PubMed Abstract 8804070, also cited as Peptides, 17/4,615-8(1996)
	Kelley et al., PubMed Abstract 12117573, also cited as Physiolo. Behav., 76/3,365-77(2002)
	Nystedt et al., PubMed 12354280, also cited as J. Neurochem., 82/6, 1330-42(2002)
	Tan et al., Peptides, 20, 1211-17 (1999)
	Prokai et al., Rapid Commun. Mass Spectrom. 2000, 14, 2414-2418
	Prokai et al., J. Med. Chem. 44, 1623-26 (2001), also cited at Chemical Abstract DN 135:163
L	

EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.			